Olmesartan medoxomil

被引：77

作者：

Warner G.T. ^{[1
]}

Jarvis B. ^{[1
]}

机构：

[1] Adis International Limited, Mairangi Bay, Auckland 10

来源：

Drugs | 2002年 / 62卷 / 9期

关键词：

Diastolic Blood Pressure; Losartan; Valsartan; Irbesartan; Olmesartan;

D O I：

10.2165/00003495-200262090-00005

中图分类号：

学科分类号：

摘要：

Olmesartan medoxomil is a nonpeptide angiotensin II receptor antagonist which selectively and competitively inhibits the type 1 angiotensin II receptor without affecting other receptors regulating the cardiovascular system. In well designed randomised trials, olmesartan medoxomil was significantly more effective than placebo, and at dosages of 10 to 20 mg/day was at least as effective as atenolol 50 to 100 mg/day in reducing diastolic blood pressure (DBP). At dosages of 5 to 20 mg/day, olmesartan medoxomil was more effective than captopril 12.5 to 50mg twice daily at lowering seated DBP in patients with mild to moderate hypertension in a dose titration study. Reductions in seated DBP were greater with olmesartan medoxomil 10 to 20 mg/day than losartan 50 to 100 mg/day. Olmesartan medoxomil at 20 mg/day was more effective in lowering seated DBP than losartan 50 mg/day, valsartan 80 mg/day or irbesartan 150 mg/day, and was more efficacious than losartan 50 mg/day or valsartan 80 mg/day at reducing 24-hour ambulatory systolic blood pressure. Olmesartan medoxomil has shown no clinically important pharmacokinetic interactions with digoxin, warfarin or antacid (aluminium magnesium hydroxide). Adverse events were infrequent in clinical studies of olmesartan medoxomil and were similar to those attributed to placebo. With olmesartan medoxomil, the frequency of dizziness was higher than with placebo but similar to that occurring with losartan, valsartan and irbesartan.

引用

页码：1345 / 1353

页数：8

共 34 条

[11]

Laeis P., Nussberger J., Puchler K., Et al., Dose-response relationship of the oral angiotensin II-antagonist CS-866 in healthy male subjects, J Hypertens, 17, SUPPL. 3, (1999)

[12]

Puchler K., Nussberger J., Laeis P., Et al., Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients, J Hypertens, 15, 12 PART 2, pp. 1809-1812, (1997)

[13]

Kawaratani T., Laeis P., Puchler K., Et al., The effect of an antacid (aluminum magnesium hydroxide) on the pharmacokinetics and safety of the oral antiotensin II-antagonist CS-866 in healthy, male subjects, J Hypertens, 17, SUPPL. 3, (1999)

[14]

Kawaratani T., Puchler K., Laeis P., Et al., Steady state pharmacokinetics of CS-866, a novel angiotensin II-receptor antagonist in elderly and young hypertensive patients, J Hum Hypertens, 13, (1999)

[15]

Laeis P., Puchler K., Witte P., Et al., Pharmacokinetics of the new oral angiotensin II-antagonist CS-866, Eur J Clin Pharmacol, 52, SUPPL., (1997)

[16]

Kawaratani T., Puchler K., Laeis P., Et al., Pharmacokinetics of RNH-6270, the active metabolite of the oral angiotensin II-antagonist CS-866, in healthy, male subjects, J Hypertens, 17, SUPPL. 3, (1999)

[17]

Laeis P., Puchler K., Witte P.U., Et al., The pharmacokinetic profile of CS-866, J Hypertens, 15, SUPPL. 4, (1997)

[18]

Puchler K., Nussberger J., Witte P.U., Et al., Pharmacokinetic, safety and tolerability studies of the oral angiotensin II-antagonist olmesartan medoxomil in young, elderly and verly elderly patients with hypertension, J Hypertens, 19, SUPPL. 2, (2001)

[19]

Laeis P., Puchler K., Von Bergmann K., A comparative pharmacokinetic, safety and tolerability trial of the oral angiotensin II-antagonist olmesartan medoxomil in subjects with varying degrees of renal impairment and in health volunteers, J Hypertens, 19, SUPPL. 2, (2001)

[20]

Puchler K., Laeis P., Kawaratani T., Et al., The effect of the combination of the oral angiotensin II-antagonist CS-866 and warfarin on pharmacodynamics, pharmacokinetics and safety in healthy, male subjects, J Hypertens, 17, SUPPL. 3, (1999)

← 1 2 3 4 →